Charlson Comorbidity Index predicts patient outcome, in cases of inoperable non-small cell lung cancer treated with radiofrequency ablation
Authors:
- Michael D. BelandMBMichael D. Beland
- Jason T. MachanJMJason T. Machan
- Thomas DiPetrilloTDThomas DiPetrillo
- Damian E. DupuyDDDamian E. Dupuy
- 1 December 2012
- journal article
- clinical trial
- Published by Elsevier in European Journal of Radiology
- Vol. 81 (12) , 4167-4172
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study)The Lancet Oncology, 2008
- Age and Comorbidity As Independent Prognostic Factors in the Treatment of Non–Small-Cell Lung Cancer: A Review of National Cancer Institute of Canada Clinical Trials Group TrialsJournal of Clinical Oncology, 2008
- Pulmonary Radiofrequency Ablation: Long-term Safety and Efficacy in 153 PatientsRadiology, 2007
- Radiofrequency ablation for the treatment of non–small cell lung cancer in marginal surgical candidatesThe Journal of Thoracic and Cardiovascular Surgery, 2005
- Observation-Only Management of Early Stage, Medically Inoperable Lung CancerChest, 2002
- Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIAChest, 2000
- Percutaneous Radiofrequency Ablation of Malignancies in the LungAmerican Journal of Roentgenology, 2000
- Revisions in the International System for Staging Lung CancerChest, 1997
- Prognostic value of histology in patients with non-small cell lung cancerLung Cancer, 1997
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987